Skeletal muscle anabolism in patients with advanced cancer

The Lancet Oncology

Volumn 16, Issue 1, 2015, Pages 13-14

  Baracos, Vickie E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR; ACTIVIN RECEPTOR IIB; ANAMORELIN; ENOBOSARM; MUSCLE PROTEIN; PLACEBO; SELUMETINIB; UNCLASSIFIED DRUG; ANABOLIC AGENT; APPETITE STIMULANT; HYDRAZINE DERIVATIVE; OLIGOPEPTIDE;

ABSENCE OF SIDE EFFECTS; ADVANCED CANCER; BIOSYNTHESIS; CACHEXIA; CANCER SURVIVAL; COMORBIDITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG TOLERABILITY; HUMAN; INFLAMMATION; MUSCLE ATROPHY; MUSCLE HYPERTROPHY; MUSCLE MASS; MUSCLE STRENGTH; NONHUMAN; NOTE; NUTRITIONAL STATUS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN SYNTHESIS; SENESCENCE; SKELETAL MUSCLE; COMPLICATION; FEMALE; MALE; NEOPLASM;

ANABOLIC AGENTS; APPETITE STIMULANTS; CACHEXIA; FEMALE; HUMANS; HYDRAZINES; MALE; NEOPLASMS; OLIGOPEPTIDES;

EID: 84926124085     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)71185-4     Document Type: Note

References (10)

1. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008, 9:629-635.
2. Kir S, White JP, Kleiner S, et al. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature 2014, 513:100-104.
3. Zhou X, Wang JL, Lu J, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010, 142:531-543.
4. Dobs AS, Boccia RV, Croot CC, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol 2013, 14:335-345.
5. Garcia JM, Boccia RV, Graham CD, et al. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol 2014, published online Dec 16. http://dx.doi.org/10.1016/S1470-2045(14)71154-4.
6. Prado CM, Sawyer MB, Ghosh S, et al. Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential?. Am J Clin Nutr 2013, 98:1012-1019.
7. Kortebein P, Ferrando A, Lombeida J, Wolfe R, Evans WJ Effect of 10 days of bed rest on skeletal muscle in healthy older adults. JAMA 2007, 297:1772-1774.
8. Prado CM, Bekaii-Saab T, Doyle LA, et al. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br J Cancer 2012, 106:1583-1586.
9. MacDonald AJ, Johns N, Stephens NA, et al. Habitual myofibrillar protein synthesis is normal in patients with upper GI cancer cachexia. Clin Cancer Res 2014, published online Nov 4. 10.1158/1078-0432.CCR-14-2004.
10. Winter A, MacAdams J, Chevalier S Normal protein anabolic response to hyperaminoacidemia in insulin-resistant patients with lung cancer cachexia. Clin Nutr 2012, 31:765-773.